TFRC and cervical carcinoma: Desferal (deferoxamine) controls the expression of human copper transporter 1 and transferrin receptor 1 via Sp1, and it exhibited synergistic cytotoxicity in combination with oxaliplatin in human cervical cancer cells [22].